Ampligen: A General Overview and the Plan for ME/CFS & Long Covid

January 27, 2022

Solve ME: For the second installment in our clinical diagnostics and treatments webinar series, Solve M.E. welcomes Tom Equels and Dr. David R. Strayer, two leaders from bio-pharma company AIM ImmunoTech to discuss their plans for clinical studies of their investigational drug Ampligen in ME/CFS and Long Covid. In addition, Dr. Charles Lapp and Gunnar Gottschalk, PhD, will share insights from real- world use of Ampligen to treat patients with ME/CFS and Long Covid.

View the full presentation here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

AIM ImmunoTech Inc. published this content on 28 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 January 2022 15:02:08 UTC.